B+
Bull case
25%
Probability
Target price
$875.00
Analysis reference price unavailable
Analysis 2026-10-06 · RankAlpha Sentiment Codex
REGN
RegeneronBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Q2 revenue rose 17% to $4.291 billion, with Dupixent global sales up 38%, U.S. EYLEA HD sales up 52% and Libtayo global sales up 30%.
Posture
Constructive
Lead driver
Value
What changed
9 setup hits (3d) with net bullish as of 2026-10-25.
What can break
Certain wholly owned U.S. products are subject to Medicaid most-favored-nation pricing commitments; financial exposure is undisclosed. [#REL-f8958f15-0718-40a7-8e24-faad173841d6]
Momentum
81
Value
63
Sentiment
45
Setup hits (3d)
9 · Net Bullish
AI TargetsBase $730.00 · Bull $875.00 · Bear $560.00Analysis 2026-10-06; returns require an exact persisted reference.
Earnings
40 · Non-qualifying
Next 2026-10-30 · BMO
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-06 • Model: RankAlpha Sentiment Codex
Earnings Setup
As of 2026-10-26 • RankAlpha AI
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $870.69
Why
Momentum81 · Δ7d -2.2
Value63 · Δ7d -0.1
Sentiment45 · Δ7d -1.4
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Earnings surprise screen
40Non-qualifying2026-10-30 bmo
Regeneron’s Oct. 30 pre-market date is confirmed by the company, and its Q2 update cited product and label-expansion developments. Q3 consensus EPS and revenue are available, but no positive EPS revision, whisper, or revenue revision was verified; the share price rose over the five sessions through Oct. 23, yet no recent session showed volume above 1.5x normal.
Screen as of 2026-10-26. Window 2026-10-26 to 2026-10-30.
Confirming evidence
- • 9 setup hits (3d) with net bullish as of 2026-10-25.
- • Next scheduled catalyst: earnings 2026-10-30 · BMO.
- • Pre-earnings setup: 40 / non-qualifying.
Contradictions & invalidation
- • Certain wholly owned U.S. products are subject to Medicaid most-favored-nation pricing commitments; financial exposure is undisclosed. [#REL-f8958f15-0718-40a7-8e24-faad173841d6]
- • EYLEA competition includes Amgen's U.S. biosimilar Pavblu; the packet does not quantify erosion. [#REL-6b6d333f-4498-44b9-a8fd-9deefa05392c]
- • Up to $7 billion in alliance milestones is contingent, not contracted near-term revenue.
Catalyst clock
2026-10-30 · BMO
Third-quarter collaboration-profit realization
Lead driver: Value · See fundamentals
Momentum
81
8% active weight
Current posture
7d trendSoftening
Δ7d
-2.2
Δ21d
+4.4
Value
63
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-1.2
Sentiment
45
45% active weight
Current posture
7d trendSoftening
Δ7d
-1.4
Δ21d
-24.0
Why this grade
Composite grade B. Momentum 80.9 / Value 62.9 / Sentiment 44.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-06. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$730.00
Analysis reference price unavailable
Analysis 2026-10-06 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$560.00
Analysis reference price unavailable
Analysis 2026-10-06 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$82.88B
Beta
0.40
Shares Out
102.96M
P/E (TTM)
18.1
P/S (TTM)
5.63
P/FCF (TTM)
22.26
Rev YoY
+16.7%
EPS YoY
-4.5%
Gross Margin
+81.5%
Op Margin
+26.9%
Net Debt
-$5.64B
Current Ratio
3.34
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data